#USA #California #Terumo Neuro #WEB Device #Aneurysm Treatment

Celebrating 15 Years of the WEB™ Device

Terumo Neuro, a subsidiary of Terumo Corporation, is proud to celebrate the fifteenth anniversary of its groundbreaking WEB™ device, which has significantly transformed the treatment landscape for aneurysms. With over 25,000 devices implanted globally between 2010 and 2025, the WEB™ has showcased its clinical efficacy and safety, making it a trustworthy option for healthcare professionals dealing with wide-neck bifurcation aneurysms.

A Breakthrough in Neurovascular Treatment

Since its introduction to the market in October 2010 after receiving CE mark approval in Europe, the WEB™ device has established itself as a pioneering tool in neurovascular care. Designed to treat wide-necked bifurcation aneurysms, it offers a clinically proven, single-device solution, simplifying procedures and enhancing patient outcomes. The first implant was expertly performed by Professor Joachim Klisch in Germany, signaling a new era in aneurysm treatment.

Clinical Evidence Supporting the WEB™ Device

The device’s reliability is backed by extensive clinical research, including seven studies of good clinical practices and over 200 peer-reviewed publications. During its fifteen years of application, the WEB™ technology has reshaped treatment methods, providing a safe and effective alternative to traditional approaches, which often require multiple devices and longer procedural times.

A Statement from Leadership

Carsten Schroeder, President and CEO of Terumo Neuro, emphasized the device's significant impact: "The WEB device has set a new standard in the treatment of aneurysms and has played a crucial role in our mission to revolutionize neurovascular care. With 15 years of proven clinical success, WEB continues to improve patient outcomes while minimizing the necessity for multiple devices and lengthy procedures. As we celebrate this milestone, we remain committed to innovating alongside leading physicians worldwide to shape the future of neurovascular care.”

Redefining Aneurysm Treatment with the WEB™ Device

The WEB™ device is recognized as the first intravascular flow disruption device globally, crafted for the treatment of cerebral aneurysms from within the aneurysm sac itself. Unlike traditional treatments that necessitate stents and coils, the WEB™ minimizes the need for dual antiplatelet therapy, simplifying procedures and enhancing patient safety with its singular design.

Noteworthy Clinical Milestones

The clinical data supporting the WEB™ device includes outstanding accomplishments:

• - Unmatched Clinical Evidence: The device has been evaluated in over 600 patients across seven pivotal clinical trials, accumulating more than 1,464 patient-years without any recorded re-bleeding events in treated aneurysms.
• - Proven Long-term Safety and Durability: Five-year follow-up data from WEB-IT, WEBCAST, and WEBCAST 2 trials reaffirm the sustained efficacy and safety of the WEB system, showing no device-related morbidity or mortality.
• - Expanding Treatment Options: The introduction of the WEB 17 system provides a low-profile alternative for treating smaller aneurysms, enhancing precision and flexibility for a broader range of cases.

Terumo Neuro's commitment to advancing neurovascular technology shines through the continuous evolution of the WEB™ device. Having treated over 25,000 patients worldwide, the WEB™ remains the preferred choice for physicians seeking reliable solutions for wide-neck bifurcation aneurysms.

About Terumo Neuro

Previously known as MicroVention, Inc., Terumo Neuro's mission is to create and deliver game-changing innovations that redefine what's possible in neuroendovascular treatment, significantly advancing both physician practice and patient outcomes. Founded in 1997 and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products aimed at treating cerebral aneurysms, ischemic strokes, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro distributes its products in over seventy countries through a direct sales force and strategic distribution partnerships, with manufacturing sites located in Aliso Viejo, California, and San José, Costa Rica.

For more information about Terumo Neuro's advancements and offerings, visit www.terumoneuro.com.

About Terumo Corporation

As a leading global medical technology company, Terumo (TSE4543) has spent the last century dedicated to contributing to society through health care. Headquartered in Tokyo and operating globally, Terumo employs over 30,000 employees worldwide, providing innovative medical solutions in over 160 countries and regions. Starting as a thermometer manufacturer, Terumo has continually supported healthcare, expanding its portfolio to encompass vascular intervention solutions, cardiovascular surgery products, essential clinical medical supplies, blood transfusion technology, and cellular therapy solutions. Terumo is dedicated to being useful to patients, healthcare professionals, and society at large.

For a complete list of indications for use, please refer to the WEB™ Embolization System page.

(The information provided may not represent the approved indications for every country or market. Please refer to the instructions for use specific to the relevant market/country.)